Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for JARDIANCE
- Bioequivalence Study of Empagliflozin 25 mg Film Coated Tablets of Humanis, Turkey and Jardiance (Empagliflozin) 25 mg Film-coated Tablets of Boehringer Ingelheim International GmbH, Germany in Normal, Healthy, Adult, Human Subjects Under Fasting Co
- EMPagliflozin After Aortic Valve Replacement
- SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
- Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes
- The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
- SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis
- Safety and Efficacy of Empagliflozin in Hemodialysis
- Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
- Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
- meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
- " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "
- Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy
- Use of Empagliflozin to Treat Prediabetes
- Empagliflozin in the Prevention of Cardiotoxicity in Cancer Patients Undergoing Chemotherapy Based on Anthracyclines
- Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
- Empagliflozin in Hypertrophic Cardiomyopathy
- Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
- Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes
- A Study in Healthy Humans to Assess the Relative Bioavailability of One Fixed-dose Combination Tablet Empagliflozin/Metformin Versus Jardiance® Tablet and Glifage® Tablet Administered Together
- SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
- Effect of UGT Genetic Variation on Pharmacokinetics of Empagliflozine
- Effect of Empagliflozin on Urinary Excretion of Adenosine and Osteocyte Function in Patients With Chronic Kidney Disease
- Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia
- Empagliflozin in Adolescent Diabetes
- Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers
- Empagliflozin and Cardiac Remodelling in People Without Diabetes
- Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia
- Pharmacological Reduction of Right Ventricular Enlargement
- Renohemodynamic Effects of Combined empagliflOzin and LosARtan
- Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD
- Dapagliflozin vs Empagliflozin on Flow Mediated Dilation in Type 2 Diabetes Mellitus
- Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study)
- SGLT2 Inhibitors in Glomerular Hyperfiltration
- Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency
- Quadruple Oral Combination Therapy for Type 2 Diabetes Mellitus : Glycemic Control by Thiazolidinedione (TZD) or Sodium Glucose Co-transporter 2 (SGLT-2) Inhibitor as an add-on Therapy in Type 2 Diabetes Mellitus After Failure of an Oral Triple Anti
- Metabolic Effects of the SGLT-2 Inhibitor Empagliflozin in Patients With Diabetic Nephropathy (MEDiaN)
- SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease
- Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production
- Drug Interaction Study Between Dorzagliatin and Empagliflozin
- Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.
- Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults
- Gemigliptin, Dapagliflozin, Empagliflozin DDI Study
- EMPA Acute Heart Failure
- The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix Insulin
- Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetES
- Empagliflozin and Sympathetic Nerve Traffic
- SGLT2 Inhibition in Combination With Diuretics in Heart Failure
- Empagliflozin in Renal Transplant Recipients
- SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk
- Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 Diabetes
- Empagliflozin in Post-Transplantation Diabetes Mellitus
- Empagliflozin and Renal Oxygenation in Healthy Volunteers
- Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction
- SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
- Empagliflozin Impact on Hemodynamics in Patients With Heart Failure
- Empagliflozin vs Metformin in PCOS
- Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes
- The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes
- Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 Diabetes
- Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study
- JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus
- SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.
- The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 Inhibitors
- The Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Advanced Glycation End Products
- Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study
- SGLT2 Inhibition and Left Ventricular Mass
- Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 Diabetes
- Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
- Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus
- Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function
- Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
- Daily Use of JARDIANCE® Tablets in Japanese Elderly Patients With Type 2 Diabetes Mellitus
- Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
Clinical trials list
click for details